Abstract
Drug development of cholesteryl ester transfer protein (CETP) inhibition to prevent coronary heart disease (CHD) has yet to deliver licensed medicines. To distinguish compound from drug target failure, we compared evidence from clinical trials and Mendelian randomization (MR) results. Findings from meta-analyses of CETP inhibitor trials (≥ 24 weeks follow-up) were used to judge between-compound heterogeneity in treatment effects. Genetic data were extracted on 190+ pharmacologically relevant outcomes; spanning 480,698-21,770 samples and 74,124-4,373 events. Drug target MR of protein concentration was used to determine the on-target effects of CETP inhibition and compared to that of PCSK9 modulation. Fifteen eligible CETP inhibitor trials of four compounds were identified, enrolling 79,961 participants. There was a high degree of heterogeneity in effects on lipids, lipoproteins, blood pressure, and clinical events. For example, dalcetrapib and evacetrapib showed a neutral effect, torcetrapib increased, and anacetrapib decreased cardiovascular disease (CVD); heterogeneity p-value < 0.001. In drug target MR analysis, lower CETP concentration (per μg/ml) was associated with CHD (odds ratio 0.95; 95%CI 0.91; 0.99), heart failure (0.95; 95%CI 0.92; 0.99), chronic kidney disease (0.94 95%CI 0.91; 0.98), and age-related macular degeneration (1.69; 95%CI 1.44; 1.99). Lower PCSK9 concentration was associated with a lower risk of CHD, heart failure, atrial fibrillation and stroke, and increased risk of Alzheimer’s disease and asthma. In conclusion, previous failures of CETP inhibitors are likely compound related. CETP inhibition is expected to reduce risk of CHD, heart failure, and kidney disease, but potentially increase risk of age-related macular disease.
Competing Interest Statement
AFS has received Servier funding for unrelated work. MZ conducted this research as an employee of BenevolentAI. Since completing the work MZ is now a full-time employee of GlaxoSmithKline. None of the remaining authors have a competing interest to declare. DAL has received support from Roche Diagnostics and Medtronic Ltd for research unrelated to this paper. TRG receives funding from GlaxoSmithKline and Biogen
Funding Statement
AFS is supported by BHF grant PG/18/5033837 and the UCL BHF Research Accelerator AA/18/6/34223. CF and AFS received additional support from the National Institute for Health Research University College London Hospitals Biomedical Research Centre. MGM is supported by a BHF Fellowship FS/17/70/33482. ADH is an NIHR Senior Investigator. We further acknowledge support from the Rosetrees and Stoneygate Trust. The UCLEB Consortium is supported by a British Heart Foundation Programme Grant (RG/10/12/28456). TRG receives support from the UK Medical Research Council (MC_UU_00011/4). DOMK is supported by the Dutch Science Organization (ZonMW-VENI Grant 916.14.023). Alun DH receives support from the UK Medical Research (MC_UU_12019/1). MK is supported by the UK Medical Research Council (MR/S011676/1, MR/R024227/1), National Institute on Aging (NIH), US (R01AG062553) and the Academy of Finland (311492). DAL is supported by a Bristol BHF Accelerator Award (AA/18/7/34219), and works in a unit that recieves support from the University of Bristol and the UK Medical Research Council (MC_UU_00011/6). DAL is a National Institute of Health Research Senior Investigator (NF-0616-10102).
Author Declarations
I confirm all relevant ethical guidelines have been followed, and any necessary IRB and/or ethics committee approvals have been obtained.
Yes
The details of the IRB/oversight body that provided approval or exemption for the research described are given below:
Analyses were based on aggregated data, which received ethical approval at the source, and as such did not require further ethical approval
All necessary patient/participant consent has been obtained and the appropriate institutional forms have been archived.
Yes
I understand that all clinical trials and any other prospective interventional studies must be registered with an ICMJE-approved registry, such as ClinicalTrials.gov. I confirm that any such study reported in the manuscript has been registered and the trial registration ID is provided (note: if posting a prospective study registered retrospectively, please provide a statement in the trial ID field explaining why the study was not registered in advance).
Yes
I have followed all appropriate research reporting guidelines and uploaded the relevant EQUATOR Network research reporting checklist(s) and other pertinent material as supplementary files, if applicable.
Yes
Footnotes
Changed the title
Data Availability
All data are publicly available, as described in the methods section. Please contact AFS for access to specific files, data, or analysis scripts.
